Inotiv, Inc. · NASDAQ:NOTV
Inotiv — Bioanalytical Systems — Noble Financial Capital Markets Tenth Annual Equity Conference (January 2014)
20 slides from Inotiv's conference presentation, Jan 22, 2014
Slide 1: Noble Financial Capital Markets Tenth Annual Equity Conference
Confidential and Proprietary Noble Financial Capital Markets Tenth Annual Equity Conference Jacqueline M. Lemke President and CEO January 22, 2014
Slide 2: Safe Harbor Statement
Confidential and Proprietary Safe Harbor Statement Matters discussed in this Presentation contain forward - looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 . When used in this document, the words "anticipate," "believe," "estimate," "may," "intend," "exp
Slide 3: Presentation Outline
Confidential and Proprietary Presentation Outline Brief History Company Profile Services and Products Customers Geographic Reach Differentiators Key Financials Next Steps – Leveraging our Strengths 3
Slide 4: Brief History
Confidential and Proprietary Brief History 4 Years Events 1974 to 1988 Founded as a scientific instruments company 1988 Began providing drug development contract services 1997 Initial Public Offering (listed on NASDAQ as BASI) 1997 - 2003 Acquisitions 1997 - Products – Vetronics 1998 - UK Bioanalyti
Slide 5: Company Profile
Confidential and Proprietary Company Profile 5 Category Descriptor Business Segments Contract Research Organization : Providing In Vivo, Preclinical, Bioanalytical, and Pharmaceutical Analysis for drug developers. Scientific Instruments: Design, develop, manufacture and market products focused on ex
Slide 6: CRO Services Spanning the Drug Discovery Value Chain
Confidential and Proprietary CRO Services Spanning the Drug Discovery Value Chain 6 Preclinical Services $6.5 M * • Pre - IND and NDA enabling studies • Dose ranging studies involving acute safety monitoring of the drug • Chronic, multi - year oncogenicity and reproductive toxicology studies • Pharm
Slide 7: Products
Confidential and Proprietary Products Research Instrumentation 7 Culex® and InVivo Sampling $2.3 M * • The in vivo sampling products consist of the Culex® family of automated in vivo sampling and dosing instruments and consumables. Analytical Instruments $2.4 M * • The analytical products consist of
Slide 8: Who do we sell to? Diverse Customer Base
Confidential and Proprietary Who do we sell to? Diverse Customer Base 8
Slide 9: Where do we sell? Global Products Reach
Confidential and Proprietary Where do we sell? Global Products Reach 9 Over 1,200 Culex ® stations sold globally
Slide 10: What differentiates us?
Confidential and Proprietary What differentiates us? 10 Innovation Regulatory Excellence Customer Focus
Slide 11: Innovation - Services
Confidential and Proprietary Innovation - Services Problem: A m ethod requires specialty handling or unique study designs which are not the core competency of the larger CROs. Solution: BASi develops a method which is tailored to the needs of the client. Recent Examples: Bioanalysis Developed a meth
Slide 12: Innovation - Products
Confidential and Proprietary Innovation - Products Problem: A large majority of early research for therapeutic target validation is done via manual handling of test subjects creating high stress subjects, labor intensity, handling hazards and a need to run multiple studies to determine both PK and P
Slide 13: Culex Benefits
Confidential and Proprietary Culex ® Benefits 13 Typical PK Study Culex Automated Sampling Lab technicians 2 techs; 8 hours each – one to draw, one to record 1 tech; 2 hours to set up, remainder of the day is free Test subject - mice 36 mice; 3 sacrificed each time point 3 mice; same time points and
Slide 14: The Culex Family
Confidential and Proprietary The Culex ® Family Small Animal Sampling Culex Integrative Pharmacology - activity, dosing, physiologic monitoring, MD, UF Culex ABC Blood Sampling Large Animal Sampling Culex - L ABC Blood Sampling Culex - L Integrative Pharmacology - activity, dosing, physiologic monit
Slide 15: Regulatory Excellence
Confidential and Proprietary Regulatory Excellence Problem: Many laboratories may not have experience working with the regulatory authorities or may have had significant negative audit findings. Solution: BASi has a long history of audited quality research and regulatory control. 10 consecutive FDA
Slide 16: Customer Focus
Confidential and Proprietary Customer Focus 16 Innovation Problem: The client wanted to reduce significantly the concept to approval process for their drug. Solution: Through continuous collaboration and consultation with the client, BASi was able to help the client reduce the cycle from the industr
Slide 17: Financial Trends
Confidential and Proprietary Financial Trends 17 2009 2010 2011 2012 2013 24.2 21.9 26.6 21.3 16.5 7.6 6.9 7.5 6.9 5.6 Services Products Annual Revenues (in millions USD) 31.8 28.8 33.1 28.2 22.1 2009 2010 2011 2012 2013 1.9% - 4.3% - 8.8% - 0.4% 12.6% Annual EBITDAR as % of Revenues Fiscal Years En
Slide 18: Income Statement
Confidential and Proprietary Income Statement (in millions USD ) 18 FY 12 FY 13 B/(W) Total Revenue 28.2 22.1 (6.1) Total COGS 21.4 15.0 Total Gross Profit 6.8 7.1 0.3 Gross Profit Margin % 24.2% 32.1% 7.9% SG&A 9.3 6.3 3.0 % of Revenue 33.1% 28.5% 4.6% Restructuring Expense 3.2 - 3.2 Operating Inco
Slide 19: Leveraging Our Strengths
Confidential and Proprietary Leveraging Our Strengths 19 Strengths Brand Equity Differentiators: Innovation, Regulatory Excellence, Client Focus Global Patent Portfolio Equity in Real Estate Future Potential Tax Savings $12.7 NOLs Expandable Instrument and Physical Capacity Opportunities Increase Ma
Slide 20: Company Contact
Confidential and Proprietary Company Contact Jacqueline M. Lemke, CEO Bioanalytical Systems, Inc. Purdue Research Park 2701 Kent Avenue West Lafayette, IN 47906 (765) 463 - 4527 jlemke@BASinc.com Agency Contact Neil Berkman Berkman Associates 1900 Avenue of the Stars Los Angeles, CA 90067 (310) 477